Lighten the load in diabetes
The #1 brand for CGM adherence: 94% ofDexcom patients report using their CGM daily*,1,2
We understand that making confident treatment decisions in type 2 diabetes can be challenging with blood glucose monitoring (BGM). This is due to long periods without glucose information, low adherence and that BGM data and HbA1c alone do not reveal glycaemic variability.3,4
Dexcom CGM is a wearable, convenient way for patients to measure and track glucose levels, designed to help lighten the load in diabetes management for both you and your patients.†,5–7
With a range of features designed around your patients’ needs, Dexcom CGM can help enhance treatment adherence with greater reductions in HbA1c, which can help lower the risk for long-term complications.†,‡,2,8,9
Approved for use acrossmultiple wear locations§,||,¶,5–7
Diverse range of displaydevices#,**,††,5–7
Customisable smart alerts andsharing features: 86% ofpatients say Dexcom CGMholds them accountable in theirdiabetes care‡‡,§§,||||,10
Waterproof up to 2.4metres for 24 hours§§,¶¶,5
Dexcom CGM empowers patients to takeownership of their diabetes†,11–14
Patients using Dexcom CGM reported significant improvements in health, wellbeing and diabetes-related distress vs BGM##,15
Dexcom CGM reduces HbA1c values while improving hypoglycaemia and hyperglycaemia management
Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility
1.8% reduction in HbA1c after 6 months##,16
Patients reported feeling safer, withthe assurance of CGM alerts##,***,16
Reduced hypoglycaemia andhyperglycaemia15,17–19
Dexcom CGM enables you todeliver more effective, efficientand meaningful care for yourpatients with diabetes†,‡‡,†††,20–23
Ready to learn how Dexcom CGM could lighten the load for you and your patients?
Dexcom CGM systemsem power patients to take ownership of their diabetes†,11–14
Fits flexibly into patients' lives, which may increase adherence‡,2
Patients can easily reflect and adjust their habits with personalised glucose insights. Using Dexcom CGM can provide greater awareness of food and activity choices.5,6,24,25
Dexcom Education, your go-to resource for diabetes learning and product training.
Learn more about Dexcom CGM and how to offer the best care for your patients.
Meet Frank: 67 years old T2D for 10 years
Frank struggles with lowering his HbA1c despite his efforts to eat healthily. With Dexcom CGM, he gained actionable insights and finally made progress
Seamless integrationinto your patientstreatmentmanagement
User-led onboarding is designed to ensure all your patients can get started on their own, with minimal oversight.#,5–7
92% of surveyed Dexcom ONE+ users find it somewhat easy or very easy to use‡‡‡,26
Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility
Maximise appointment time with moreconvenient access to patient data§§§,5,6
The Dexcom app offers clear, actionable insights into key diabetes metrics, making it easier to review patient progress and tailor treatment during clinic visits.§§§,5,6
See how Dexcom CGM could simplify diabetes management for your clinical practice.
See how Dexcom CGM could simplify diabetes management for your clinical practice.
#1 clinically proven: DexcomCGM offers advanced alertfeatures that can helpsafeguard your patients foreffective outcomes27–30
Dexcom CGM is available on prescription for patients with type 2 diabetes on multiple daily injections who meet any of the following criteria:
• Recurrent or severe hypoglycaemia
• Impaired hypoglycaemia awareness
• Test at least 8 times a day
• Inability to self-monitor due to a condition or disability
• Recurrent or severe hypoglycaemia
• Impaired hypoglycaemia awareness
• Test at least 8 times a day
• Inability to self-monitor due to a condition or disability
Get in touch to learn more about the #1clinically proven CGM brand and help lightenthe load in diabetes27
*Based on self-reported treatment (CGM) compliance by type 1 and type 2 users of Dexcom, Abbott, and Medtronic in the United States. † Compared to self-monitoring blood glucose testing. ‡ US study: 7669 participants. § Dexcom ONE+ patients aged 7 years or older can use the back of the upper arm or abdomen; patients 2–6 years old can also choose their upper buttocks. || Dexcom G7 patients can use their abdomen and back of upper arm; patients 2–6 years old can also choose their upper buttocks. ¶ Dexcom G6 patients can use their abdomen and back of upper arm; patients 2–17 years old can also choose their upper buttocks. # Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility. **Simultaneous use of a compatible smartphone is required to receive readings on a compatible smartwatch. ††Compatible smartphone is required to pair a new Dexcom G7. ‡‡ An internet connection is required for users to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. §§ Keep display device close to the sensor. Bluetooth doesn’t work as well through water. Alerts and readings will not be provided if signal loss occurs. During signal loss, use your meter to check your glucose levels and make any treatment decisions. |||| Results obtained with previous generation of Dexcom Clarity and Dexcom CGM. ¶¶ The Dexcom ONE+ Sensor is waterproof and may be submerged under 2.4 metres of water for up to 24 hours. ##Results obtained with previous generation of Dexcom CGM system and are applicable to Dexcom ONE+ given similar feature sets and better performance and usability. ***Reports from HCPs or Dexcom CGM users based on notes from HCPs who participated in this study.25 ††† Healthcare professionals should use information in the software in conjunction with other clinical information available to them. ‡‡‡ Based on responses to a question (Overall, how difficult or easy is it to use the Dexcom ONE+?) in a survey from new Dexcom ONE+ users in EMEA, N=162. §§§Compared to previous in-app experience, Dexcom G7/Dexcom ONE+ now includes Dexcom Clarity reports in-app, events with glucose insights and customizable target range.
1. Survey among patients with diabetes in the US, 2024, n=430. 2. Nemlekar PM, et al. Diabetes Ther. 2024;15(3):639–648. 3. Hirose T, et al. Diabetes Care. 2011;34(3):596-597. 4. Adolfsson P, et al. Eur Endocrinol. 2018;14(1):24-29. 5. Dexcom ONE+ user guide, 2023. 6. Dexcom G7 user guide, 2023. 7. Dexcom G6 user guide, 2023. 8. Stratton IM, et al. BMJ. 2000;321(7258):405 412. 9. DCCT and EDIC Research Group. Diabetes Care. 2016;39(5):686–693. 10. Polonsky WH & Fortmann AL. J Diabetes Sci Technol. 2022;16(1):97–105. 11. Srivastava SB, et al. Am J Lifestyle Med. 2023;17(3):359–364. 12. Lawton J, et al. BMC Endocr Disord. 2018;18(1):12. 13. Williams L, et al. Afr J Prim Health Care Fam Med. 2023;15(1):e1–e6. 14. Polonsky WH, et al. Diabetes Care. 2017;40(6):736–741. 15. Lind N, et al. Diabetes Care. 2024;47(5):881–889. 16. Elliott J, et al. Diabet Med. 2025;42(4):e15519. 17. Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143–147. 18. Beck RW, et al. JAMA. 2017;317(4):371–378. 19. Lind M, et al. Diabetes Care. 2021;44(1):141–149. 20. Edelman SV, et al. Prim Care Diabetes. 2021;15(2):199–207. 21. Miller EM. Clin Diabetes. 2020;38(5):429–438. 22. Akturk HK, et al. Diabetes Technol Ther. 2021;23(S1):S21–S26. 23. Dexcom. Data on file, 2023. 24. Ehrhardt N, et al. J Diabetes Sci Technol. 2019;13:271-275. 25. Bergenstal RM, et al. Diabetes Technol Ther. 2021;(2):128-132. 26. Dexcom survey among Dexcom CGM new customers in the UK, Belgium, Spain and Netherlands, 2024, n=162. Data on file. 27. Dexcom. Data on file, 2025. 28. Acciaroli G, et al. J Diabetes Sci Technol. 2022;16(3):677–682. 29. Aly A, et al. Diabetes Technol Ther. 2024;26(S2):A254–A255. 30. Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155–158.